TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19549094

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10-40 mg OD)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20-80 mg OD)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg OD)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg OD)
Number of subjects: 69
Study: 16672210

Group type: EXPERIMENTAL
Intervention: Energy drink (containing sucrose and caffeine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lemonade
Number of subjects: 10
Study: 15233283

Group type: EXPERIMENTAL
Intervention: Acetazolamide stress
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ARG method with assumed Vd
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Baseline CBF and change in CBF
Number of subjects: 12
Study: 14617265

Group type: EXPERIMENTAL
Intervention: Laser Doppler fluxmetry (LDF)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Photoplethysmography (PPG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of LDF and PPG
Number of subjects: 14
Study: 10735790

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg. kg(‐1). min(‐1) continuous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg bolus followed by placebo continuous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0
Study: 8737620

Group type: EXPERIMENTAL
Intervention: Intranasal carbocalcitonin (80 U MRC daily for 12 months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (untreated women)
Number of subjects: 150
Study: 1591369

Group type: EXPERIMENTAL
Intervention: Combination of cisplatin, decarbazine, carmustine, and tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological response modifiers (interleukin‐2 and alpha‐interferon)
Number of subjects: 0
Study: 3893528

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Levobunolol 1%
Number of subjects: 88

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 88
Study: 31102644

Group type: EXPERIMENTAL
Intervention: Moderate sedation
Number of subjects: 585

Group type: COMPARATOR
Intervention: Deep sedation
Number of subjects: 585
Study: 29424335

Group type: EXPERIMENTAL
Intervention: Test preparation (entecavir tablet)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference preparation (entecavir tablet)
Number of subjects: 0
Study: 27343787

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 128

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 128
Study: 24423018

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pregabalin 75 mg twice daily
Number of subjects: 40
Study: 23346797

Group type: EXPERIMENTAL
Intervention: Patients with secondary and higher education
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (patients with primary and vocational education)
Number of subjects: 240
Study: 20118030

Group type: EXPERIMENTAL
Intervention: Prophylactic pegfilgrastim use (all cycles of chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reactive pegfilgrastim use (at clinicians' discretion)
Number of subjects: 0
Study: 18687421

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Control conditions (waitlist vs. psychological control)
Number of subjects: 1851
Study: 15833779

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study: 12457662

Group type: EXPERIMENTAL
Intervention: Zyoptix wavefront-guided LASIK
Number of subjects: 12

Group type: COMPARATOR
Intervention: PlanoScan LASIK
Number of subjects: 12
Study: 10404713

Group type: EXPERIMENTAL
Intervention: Single item visual analogue scales (VASs) for irritability, tension, depression, and mood swings; Premenstrual Tension Syndrome Observer (PMTS‐O) and Self‐Rating (PMTS‐SR) scales
Number of subjects: 0
Study: 7675608

Group type: EXPERIMENTAL
Intervention: Subjective condition (model observed from the rear)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Looking-glass condition (model facing the subject, viewing performance opposite directions)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Objective condition (model facing the subject)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Retention across all conditions
Number of subjects: 30
Study: 2200296

Group type: EXPERIMENTAL
Intervention: Anjuvac (modified alginate conjugated birch pollen extract)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Alutard (aluminium adsorbed birch pollen extract)
Number of subjects: 63
Study: 7021266

Group type: EXPERIMENTAL
Intervention: Fentiazac 5% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31260794

Group type: EXPERIMENTAL
Intervention: Weight-driven recommendation of restricted fluid intake, diuretics, and ultrafiltration initiated from 48 hours up to 14 days after admission.
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 1440
Study: 28782974

Group type: EXPERIMENTAL
Intervention: Experience Sampling Methodology (ESM)
Number of subjects: 100
Study: 26187183

Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community health workers using an Android app, focusing on medication use and lifestyle modifications.
Number of subjects: 2086

Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by community health workers using an Android app.
Number of subjects: 2086
Study: 24172699

Group type: EXPERIMENTAL
Intervention: Insulin plus alpha-lipoic acid 300 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 30
Study: 21645507

Group type: EXPERIMENTAL
Intervention: Exenatide 5 μg twice a day (titrated to 10 μg twice a day after 1 month)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Glimepiride 1 mg three times a day (titrated to 2 mg three times a day after 1 month)
Number of subjects: 111
Study: 19468259

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard procedure to reach a treatment agreement (control)
Number of subjects: 220
Study: 16433641

Group type: EXPERIMENTAL
Intervention: Cervitec varnish
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15232804

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% added to cardioplegia solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no sevoflurane)
Number of subjects: 21
Study: 11389784

Group type: EXPERIMENTAL
Intervention: Estrogen or hormone replacement therapy (ERT or HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9517609

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 84 microg twice a day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8044121

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice
Number of subjects: 0
Study: 3191663

Group type: COMPARATOR
Intervention: Timolol (non-selective beta-blocker, 10 mg b.i.d. for 5 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective beta-blocker, 100 mg b.i.d. for 5 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Timolol (non-selective beta-blocker)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective beta-blocker)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both beta-blockers
Number of subjects: 21
Study: 19546012

Group type: EXPERIMENTAL
Intervention: Single-row suture anchor repair
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Double-row suture bridge repair
Number of subjects: 8
Study: 761001

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study: 30529466

Group type: EXPERIMENTAL
Intervention: Presence of abnormal PTE bone signal and/or erosion
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Presence of PTE abnormalities
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Baseline PTE abnormalities
Number of subjects: 961
Study: 30283184

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg loading dose over 15 min, followed by 10 mg/kg/h for 1 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paracetamol (10 mg/kg infusion started with induction and continued for 1 h)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 60
Study: 26890200

Group type: EXPERIMENTAL
Intervention: Zinc, selenium, glutamine, and metoclopramide
Number of subjects: 229

Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 229
Study: 25407227

Group type: EXPERIMENTAL
Intervention: Dietary intervention consisting of olive oil for cooking, an olive oil based spread, and a daily supplement drink enriched with Vitamin D (10 microgram daily) and marine omega‐3 fatty acids (2 g daily) for 6 weeks preconception
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control diet of sunflower seed oil for cooking, a sunflower oil based spread, and a daily supplement drink without added Vitamin D or marine omega‐3 fatty acids
Number of subjects: 110
Study: 22957013

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment at a dose of 50 IU/kg/week for 3 injections over 18 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no EPO treatment)
Number of subjects: 18
Study: 19440168

Group type: EXPERIMENTAL
Intervention: Discoblock (intradisc injection of 0.75 mL of 0.5% bupivacaine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Discography (1.5 mL of contrast medium)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Discoblock
Number of subjects: 42

Group type: COMPARATOR
Intervention: Discography
Number of subjects: 42
Study: 17487928

Group type: EXPERIMENTAL
Intervention: Cranberry juice (cranberry-OAC, n = 89)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo beverage (placebo-OAC, n = 88)
Number of subjects: 177

Group type: COMPARATOR
Intervention: OAC alone (non-placebo-OAC, n = 712)
Number of subjects: 177
Study: 12701864

Group type: EXPERIMENTAL
Intervention: BSE with single-drop instillation of mitomycin C (MMC) 0.02% at the end of the surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BSE with postoperative MMC 0.02% drops twice a day for 5 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BSE with intraoperative MMC 0.02%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bare scleral excision (BSE)
Number of subjects: 80
Study: 10880548

Group type: EXPERIMENTAL
Intervention: Comprehensive Menopausal Assessment (CMA) intervention program
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 76
Study: 8818848

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 530

Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times daily for 10 days
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 530
Study: 1373360

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 32
Study: 3904392

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31162592

Group type: EXPERIMENTAL
Intervention: Photovoice exercise in diabetes self-management education program
Number of subjects: 37
Study: 26002873

Group type: EXPERIMENTAL
Intervention: Integrated Violence Prevention Treatment (IVPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (anger management session and psycho-educational sessions)
Number of subjects: 0
Study: 25818976

Group type: EXPERIMENTAL
Intervention: Isoperistaltic stapled side-to-side anastomosis (SSSA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Antiperistaltic stapled side-to-side anastomosis (SSSA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 22868247

Group type: EXPERIMENTAL
Intervention: Intermittent LHRH therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Continuous LHRH therapy
Number of subjects: 31
Study: 21209062

Group type: EXPERIMENTAL
Intervention: Scorpion antivenom plus prazosin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prazosin alone
Number of subjects: 70
Study: 19684500

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 12 sessions (5 sessions per week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 19
Study: 17373863

Group type: EXPERIMENTAL
Intervention: First ONS (oral nutritional supplement)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Second ONS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Third ONS
Number of subjects: 32
Study: 15220011

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 398
Study: 11288158

Group type: EXPERIMENTAL
Intervention: Nimodipine (n = 40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Vitamin C (n = 44)
Number of subjects: 84
Study: 9404990

Group type: EXPERIMENTAL
Intervention: Cultured allogeneic keratinocyte sheets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Op-Site treatment
Number of subjects: 0
Study: 7506159

Group type: EXPERIMENTAL
Intervention: Nimesulide 200mg twice daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Naproxen 500mg twice daily
Number of subjects: 68
Study: 3711534

Group type: EXPERIMENTAL
Intervention: 200 mg oral dipyridamole
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous dipyridamole
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 400 mg oral dipyridamole
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (200 or 400 mg)
Number of subjects: 50
Study: 31729600

Group type: EXPERIMENTAL
Intervention: R,S‐1,3‐butanediol (BD) 0.35 g kg‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31258919

Group type: EXPERIMENTAL
Intervention: Vilanterol 25 µg (VI)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 µg (FF)
Number of subjects: 1673

Group type: EXPERIMENTAL
Intervention: Combination of Vilanterol 25 µg and Fluticasone furoate 100 µg (VI 25/FF 100)
Number of subjects: 1673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1673
Study: 29211225

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 630

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 630
Study: 26374696

Group type: EXPERIMENTAL
Intervention: 20-min breathing retraining plus education
Number of subjects: 33

Group type: COMPARATOR
Intervention: 20-min standard education
Number of subjects: 33
Study: 23937597

Group type: EXPERIMENTAL
Intervention: Active marijuana (≥5.5% Δ⁹‐tetrahydrocannabinol/THC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Inactive marijuana (0.0% THC)
Number of subjects: 18
Study: 21766559

Group type: COMPARATOR
Intervention: Vitamin A or beta-carotene supplementation (placebo-controlled)
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: First trimester (0-12 weeks gestation)
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Third trimester (32-36 weeks gestation)
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Postpartum (12-18 weeks)
Number of subjects: 1435
Study: 17803665

Group type: EXPERIMENTAL
Intervention: Motor Performance Checklist (MPC)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Parent Evaluation of Developmental Status (PEDS)
Number of subjects: 339
Study: 16441522

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 301

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 301
Study: 15249277

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation (CR)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mental Stimulation (MS)
Number of subjects: 44
Study: 11747873

Group type: EXPERIMENTAL
Intervention: 23-day 20/75 regimen
Number of subjects: 33

Group type: COMPARATOR
Intervention: 21-day 30/75 regimen
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study: 9576452

Group type: EXPERIMENTAL
Intervention: Triple therapy (lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 gm b.i.d.)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole t.i.d. and amoxicillin t.i.d.)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and clarithromycin t.i.d.)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and clarithromycin b.i.d.)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dual therapy (lansoprazole b.i.d. and amoxicillin t.i.d.)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Monotherapy (lansoprazole)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Dual therapy
Number of subjects: 352

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: H. pylori positive patients
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Triple therapy and dual therapy
Number of subjects: 352
Study: 7887102

Group type: EXPERIMENTAL
Intervention: Continuous thoracic epidural fentanyl combined with 0.2% bupivacaine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Patient‐controlled intravenous morphine
Number of subjects: 21
Study: 2979269

Group type: EXPERIMENTAL
Intervention: Enteric-coated microspheres of pancreatin
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-enteric-coated pancreatin with cimetidine
Number of subjects: 14
Study: 28444123

Group type: EXPERIMENTAL
Intervention: ANAM4
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CNS‐VS
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: CogState
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: ImPACT
Number of subjects: 503

Group type: COMPARATOR
Intervention: NCATs
Number of subjects: 503
Study: 24338185

Group type: EXPERIMENTAL
Intervention: Integrated packages of care (conventional and complementary) as currently provided in the hospital
Number of subjects: 0
Study: 26030027

Group type: EXPERIMENTAL
Intervention: Mother-plus-child received intervention (M + C)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Child-only received intervention (CO)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Wait list comparison group (CG)
Number of subjects: 181
Study: 23348969

Group type: EXPERIMENTAL
Intervention: 6-week SMS USA intervention (n = 101)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Attention-matched control group aimed at improving sleep and physical activity (n = 63)
Number of subjects: 164
Study: 21498100

Group type: EXPERIMENTAL
Intervention: GH receptor blocker (pegvisomant, 5 mg/day, n=9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=11)
Number of subjects: 20
Study: 18330706

Group type: EXPERIMENTAL
Intervention: Longer L2 experience
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Shorter L2 experience
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attention to word meaning (semantic processing)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control condition (non-semantic processing)
Number of subjects: 52
Study: 16344317

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine and rituximab
Number of subjects: 88
Study: 12679756

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 665

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH, 5000 IU 3 times daily)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 665

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 665
Study: 10858919

Group type: EXPERIMENTAL
Intervention: Sulbutiamine (Arcalion) 600 mg p.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8861051

Group type: EXPERIMENTAL
Intervention: B-mode ultrasonographic scanning
Number of subjects: 13500
Study: 2405042

Group type: EXPERIMENTAL
Intervention: Injections every 3 months (21 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Injections every 6 weeks (22 patients)
Number of subjects: 43
Study: 6102637

Group type: EXPERIMENTAL
Intervention: Nurse-midwives performing post-partum tubal ligation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doctors performing post-partum tubal ligation
Number of subjects: 0
Study: 31605616

Group type: EXPERIMENTAL
Intervention: Maternal Multiple Micronutrient Supplementation (MMS)
Number of subjects: 7486
Study: 31279675

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28509605

Group type: EXPERIMENTAL
Intervention: Bio Pox™ (indigenous investigational vaccine)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Varivax™ (licensed vaccine)
Number of subjects: 252
Study: 25534151

Group type: EXPERIMENTAL
Intervention: Initial phone booster call
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Second phone booster call
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: First call contact attempts
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Second call contact attempts
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Duration of completed calls
Number of subjects: 425
Study: 23107810

Group type: EXPERIMENTAL
Intervention: High dose triamcinolone acetate
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone acetate
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (local anesthetic and adrenaline without corticosteroids)
Number of subjects: 84
Study: 21601519

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60